CLINICAL_TRIALS
trial_result
· 2026-04-21
Clinical Trial Update: PH 2 Pemigatinib in SDH-deficient GIST [Phase 2]
Summary
Phase 2 study of pemigatinib in SDH-deficient gastrointestinal stromal tumor is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: SDH Gene Mutation, Gastrointestinal Stromal Tumor | Phase 2 | Status: RECRUITING